Purpose: To establish a HPLC testing method of the content of bulk picoplatin and its impurities. Method: the separation was perform on a C18 column(4.6 mm×250 mm, 5 m) with potassium dihydrogen phosphate-aceton-...Purpose: To establish a HPLC testing method of the content of bulk picoplatin and its impurities. Method: the separation was perform on a C18 column(4.6 mm×250 mm, 5 m) with potassium dihydrogen phosphate-aceton-itrile as the mobile phase at a flow rate of 1.0 mL/min. The detecting wavelength was set at 210 nm, and the column temperature was set at 30℃. Result: in the method validation, the linear relationship modulus of picoplatin is 0.9999, the systemic precision is 0.44%, the method precision is 0.74%, the average recovery rate is 99.62%, the LOD and LOQ of picoplatin is 0.2 ng and 1.0 ng. The average resolution of picoplatin and its impurities is more than 2. Conclusion: The established method is good specificity, high sensitivity, and good repeatability which could provide scientific evidence for the quality control of picoplatin and its impurities.展开更多
The residual metal impurities in cisplatin, carboplatin and oxaliplatin were determined by ICP-AES. The samples were ignited and dissolved with HCl:HNO 3 (3:1). The method is simple and accurate. By the determination ...The residual metal impurities in cisplatin, carboplatin and oxaliplatin were determined by ICP-AES. The samples were ignited and dissolved with HCl:HNO 3 (3:1). The method is simple and accurate. By the determination of the metal residues in the samples, the calculated actual daily exposure and concentration of the metal Pd, Ir, Rh, Ru, Mo, Ni, Cr, V, Cu, Mn, Fe and Zn that were less than the permitted daily exposures (PDE) and the limited concentration permitted in the EMEA guideline on the specification limits for residues of metal catalysts or metal reagents [1] . The metal residues can de adequately removed from the active pharmaceutical ingredients and the corresponding drugs. The trace metal residues will not affect human health and lead to the safety hazard by the intravenous injection.展开更多
Miriplatin, a novel lipophilic platinum complex has been developed to treat hepatocellular carcinoma. An improvd synthetic route was designed and used to prepare the target compound. The intermediate Pt(C6H14N2)(I) 2 ...Miriplatin, a novel lipophilic platinum complex has been developed to treat hepatocellular carcinoma. An improvd synthetic route was designed and used to prepare the target compound. The intermediate Pt(C6H14N2)(I) 2 was synthesized from K 2 PtCl 4 , KI and (1R,2R)-1,2-cyclohexanediamine, Pt(C 6 H 14 N 2 )(I) 2 was reacted with AgNO 3 to prepare Pt(C 6 H 14 N 2 )(H 2 O) 2 (NO 3 ) 2 solution then was subsequently reacted with CH 3 (CH 2 ) 12 COONa in n-butanol to give target compound with satisfied yield 81%(based on Pt(C 6 H 14 N 2 )I 2 ). The structure of the target compound was identified by elemental analysis, ESI-MS, FT-IR, 1H-NMR, thermal analysis, the structure was consistent with the target compound.展开更多
文摘Purpose: To establish a HPLC testing method of the content of bulk picoplatin and its impurities. Method: the separation was perform on a C18 column(4.6 mm×250 mm, 5 m) with potassium dihydrogen phosphate-aceton-itrile as the mobile phase at a flow rate of 1.0 mL/min. The detecting wavelength was set at 210 nm, and the column temperature was set at 30℃. Result: in the method validation, the linear relationship modulus of picoplatin is 0.9999, the systemic precision is 0.44%, the method precision is 0.74%, the average recovery rate is 99.62%, the LOD and LOQ of picoplatin is 0.2 ng and 1.0 ng. The average resolution of picoplatin and its impurities is more than 2. Conclusion: The established method is good specificity, high sensitivity, and good repeatability which could provide scientific evidence for the quality control of picoplatin and its impurities.
基金The national SME technology innovation fund(11C26215305898)Kunming SME technology innovation fund(CJ2011040)
文摘The residual metal impurities in cisplatin, carboplatin and oxaliplatin were determined by ICP-AES. The samples were ignited and dissolved with HCl:HNO 3 (3:1). The method is simple and accurate. By the determination of the metal residues in the samples, the calculated actual daily exposure and concentration of the metal Pd, Ir, Rh, Ru, Mo, Ni, Cr, V, Cu, Mn, Fe and Zn that were less than the permitted daily exposures (PDE) and the limited concentration permitted in the EMEA guideline on the specification limits for residues of metal catalysts or metal reagents [1] . The metal residues can de adequately removed from the active pharmaceutical ingredients and the corresponding drugs. The trace metal residues will not affect human health and lead to the safety hazard by the intravenous injection.
基金The Yunnan science and technology project(2010DH021)Kunming Wuhua Zoon science and technology project(201037)
文摘Miriplatin, a novel lipophilic platinum complex has been developed to treat hepatocellular carcinoma. An improvd synthetic route was designed and used to prepare the target compound. The intermediate Pt(C6H14N2)(I) 2 was synthesized from K 2 PtCl 4 , KI and (1R,2R)-1,2-cyclohexanediamine, Pt(C 6 H 14 N 2 )(I) 2 was reacted with AgNO 3 to prepare Pt(C 6 H 14 N 2 )(H 2 O) 2 (NO 3 ) 2 solution then was subsequently reacted with CH 3 (CH 2 ) 12 COONa in n-butanol to give target compound with satisfied yield 81%(based on Pt(C 6 H 14 N 2 )I 2 ). The structure of the target compound was identified by elemental analysis, ESI-MS, FT-IR, 1H-NMR, thermal analysis, the structure was consistent with the target compound.
